Azenta, Inc. (AZTA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$31.33+0.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · AZTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 106.1% |
| Our one-year growth estimate | diamond | 4.2% |
Growth built into the price is above our model estimate.
The price assumes 101.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 25 industry peers · Company calendar date is not available
AZTA — CEO transition
Dated 2026-08-24
CEO — John P. Marotta: The CEO resigned but was immediately succeeded by a named Interim CEO, indicating an orderly transition rather than a sudden loss of leadership.
Why it matters: The new CEO's vision will shape Azenta's future strategy. A smooth transition can boost investor confidence.
Supportive ifA permanent CEO will be announced by the end of this fiscal quarter.
Worry ifNo announcement of a permanent CEO by the end of the current fiscal quarter.
Why it matters: Better cash flow means better efficiency and financial health.
Supportive ifCash flow from operations improves by more than 10% each year.
Worry ifCash flow from operations does not improve or drops year-over-year.
Why it matters: This range shows what management expects for performance in the next quarter.
Watch forAdjusted EBITDA guidance falls within the range of $20 million to $23 million.
Also watch forAdjusted EBITDA guidance falls outside the range of $20 million to $23 million.
Why it matters: Growth in Multiomics revenue shows that management's changes are working.
Supportive ifMultiomics revenue increases year over year by more than 10% in the next quarter.
Worry ifMultiomics revenue growth is flat or declines year over year.
Why it matters: Better cash flow is important for Azenta to support its growth and operations.
Supportive ifOperating cash flow increases from $12 million in Q2 to above $15 million in Q3.
Worry ifOperating cash flow drops more or stays below $12 million.
Why it matters: A bigger drop in adjusted EBITDA margin shows worse efficiency. It also shows poor cost control.
Worry ifAdjusted EBITDA margin may drop more than 125 basis points from fiscal 2025.
Less concerning ifAdjusted EBITDA margin may drop less than or stay around 125 basis points.
Why it matters: This will show if the company can recover from recent revenue declines. A stable or growing number suggests better execution and demand.
Watch forQ3 organic revenue growth stays the same or increases compared to last year. It is above 0%.
Also watch forQ3 organic revenue declines year over year, worse than -2%.
Why it matters: Paying back the vendor loan shows financial stability after the acquisition. It also helps future growth.
Supportive ifThelema finishes financing to pay back the vendor loan on or before the due date.
Worry ifThelema defaults on the vendor loan or fails to secure financing.
Why it matters: Success in this area is crucial for long-term growth and market positioning.
Supportive ifGood news on Multiomics revenue growth or improvements from new leaders.
Worry ifOngoing stagnation or drop in Multiomics revenue.
Why it matters: If costs rise faster than revenue, it may show bad cost management.
Worry ifCosts go up by over 12% while revenue grows less than 10%.
Less concerning ifOperating expenses grow at a rate lower than or equal to revenue growth.
Why it matters: A successful change in Multiomics would help long-term growth and better execution.
Supportive ifThere are good updates on Multiomics from new President Trey Martin.
Worry ifThere are bad updates or no progress in Multiomics.
Why it matters: A drop in organic revenue shows ongoing growth problems despite earlier guidance.
Worry ifQ4 organic revenue guidance shows a drop of about low single digits from last year.
Less concerning ifOrganic revenue guidance stays steady or grows compared to last year.
Why it matters: Better cash flow means the company is doing well and is financially healthy.
Supportive ifOperating cash flow improves from $1 million in Q3 to a higher figure in the next quarter.
Worry ifOperating cash flow drops more or stays negative.
Why it matters: Consulting expenses may hurt profits and efficiency in the short term.
Worry ifAdjusted EBITDA shows a decline below $20 million in the next quarter.
Less concerning ifAdjusted EBITDA stays above $23 million in the next quarter.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$194 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $501 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,094 loss on $10,000 · 60.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.